{ "items": [ "\n\n
\n \n 16 February 2023\n \n
\n\n \n\n \n \n \nPeople with blood cancers are among the most clinically vulnerable individuals to COVID-19 in the UK. Despite this, vaccine uptake has decreased with each subsequent dose, according to new research from the Nuffield Department of Primary Care Health Sciences.
\n \n\n\n \n 15 February 2023\n \n
\n\n \n\n \n \n \nResearchers from the Nuffield Department of Medicine\u2019s Target Discovery Institute and CAMS Oxford Institute, and the Department of Biochemistry uncovered at the molecular level how protein BIRC6 (a giant ubiquitin ligase) keeps cells alive.
\n \n\n\n \n 14 February 2023\n \n
\n\n \n\n \n \n \nThe National Cancer Research Institute (NCRI) has announced that Professor Tim Maughan, Emeritus Professor of Clinical Oncology, has been appointed their new Interim CEO.
\n \n\n\n \n 13 February 2023\n \n
\n\n \n\n \n \n \nMembers of the Department of Oncology discuss the challenges and successes they have faced in their careers in cancer research, and what society can do to pave the way for parity in STEM roles.
\n \n\n\n \n 10 February 2023\n \n
\n\n \n\n \n \n \nDesigned for talented individuals from disadvantaged and under-represented backgrounds at postgraduate level, the University\u2019s UNIQ+ internships offer research experience with Oxford\u2019s world-class academic community through seven-week projects in a wide range of subject areas and departments.
\n \n\n\n \n 9 February 2023\n \n
\n\n \n\n \n \n \nIn his inaugural article in the Proceedings of the National Academy of Sciences as an NAS member (elected 2021), Prof Mike Dustin and his research team in the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences have explained how messages are passed across the immunological synapse. The research could have implications for future vaccine development and cancer immunotherapy.
\n \n\n\n \n 23 January 2023\n \n
\n\n \n\n \n \n \nCancer Research UK (CRUK) and the National Institute for Health and Care Research (NIHR) are investing over \u00a33 million across the next five years into The University of Oxford\u2019s Experimental Cancer Medicine Centre (ECMC). The investment will enable Oxford to expand its portfolio of precision prevention and early detection cancer trials.
\n \n\n\n \n 16 January 2023\n \n
\n\n \n\n \n \n \nUniversity of Oxford Spinouts 'Celleron Therapeutics' and 'Argonaut Therapeutics' will merge to form IngenOx Therapeutics. The new company will focus on delivering new precision medicine drugs and vaccines to treat the most difficult cancers, often referred to as cold tumours.
\n \n\n\n \n 13 January 2023\n \n
\n\n \n\n \n \n \nThe CRUK Oxford Centre Annual Symposium is a celebration of the passion and commitment to cancer research that exists across the Oxford Cancer Network.
\n \n\n\n \n 12 January 2023\n \n
\n\n \n\n \n \n \nNew research from the Sir William Dunn School of Pathology shows how the effectiveness of therapeutic chimeric antigen receptors might be improved for cancer treatment.
\n \n\n\n \n 9 January 2023\n \n
\n\n \n\n \n \n \nGiampiero Valenzano - who is currently reading for a DPhil in Oncology - has been announced as a 2022/2023 Oxford Sparks Ambassador.
\n \n\n\n \n 19 December 2022\n \n
\n\n \n\n \n \n \nNew research from the Fairfax Group has identified a genetic marker that could be used to predict a patient\u2019s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.
\n \n\n\n \n 12 December 2022\n \n
\n\n \n\n \n \n \nIBD-associated colorectal cancers were found to occur in younger patients and have worse outcomes. Researchers call for urgent improvement of early detection methods to provide more risk-based and personalised care.
\n \n\n\n \n 8 December 2022\n \n
\n\n \n\n \n \n \nDr Bornschein will join the Simmons Group for a project developing strategies to identify patients at high risk of gastritis/gastric cancer.
\n \n\n\n \n 7 December 2022\n \n
\n\n \n\n \n \n \nOrganised by the NIHR Oxford Biomedical Research Centre, Professor Mark Middleton and patient representative Sue Duncombe discuss how cancer blood tests are being assessed and how they may change how cancer is diagnosed in the NHS.
\n \n\n\n \n 1 December 2022\n \n
\n\n \n\n \n \n \nThe partnership will aim to apply new immunotherapy techniques to cancer patients. It will also aim to enhance scientific outcomes in both institutions, sharing strategic initiatives and supporting clinical trials.
\n \n\n\n \n 25 November 2022\n \n
\n\n \n\n \n \n \nScientists from the University of Oxford's MRC Weatherall Institute of Molecular Medicine and the University of Birmingham have made the first bone marrow \u2018organoids\u2019 that include all the key components of human marrow. This technology allows for the screening of multiple anti-cancer drugs at the same time, as well as testing personalised treatments for individual cancer patients.
\n \n\n\n \n 23 November 2022\n \n
\n\n \n\n \n \n \nThe Leedham Lab in the Nuffield Department of Medicine (NDM) has been awarded over \u00a32M from Cancer Research UK to develop a new tool that could help guide how bowel cancer patients are treated in the future.
\n \n\n\n \n 21 November 2022\n \n
\n\n \n\n \n \n \nThis initiative, announced by the NHS England Chief Executive, is part of the drive to diagnose cancers earlier in the NHS by \u201cfast-tracking\u201d community-based diagnostic testing.
\n \n\n\n \n 16 November 2022\n \n
\n\n \n\n \n \n \nOver the summer, the Cancer Research UK Oxford Centre hosted Biochemistry Student - Anastacia Mozie - as part of Health Data Research UK's Black Internship Programme. Read about Anastacia's time with the centre on the Cancer Research UK website.
\n \n\n